ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2030

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG

Cetuximab (Erbitux, C225)

cetuximab 500 mg/m² repeated every two weeks.

DRUG

trifluridine/tipiracil

Trifluridine/tipiracil 35 mg/m² (orally for 5 days, followed by 9 days off)

DRUG

Bevacizumab ( Avastin)

bevacizumab 5 mg/kg

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT07012954 - ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC | Biotech Hunter | Biotech Hunter